Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery

Am J Hematol. 2022 Feb 1;97(2):E51-E54. doi: 10.1002/ajh.26409. Epub 2021 Dec 11.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anemia, Hemolytic, Autoimmune / complications
  • Anemia, Hemolytic, Autoimmune / prevention & control*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cardiac Surgical Procedures
  • Complement Inactivating Agents / therapeutic use*
  • Coronary Disease / complications
  • Coronary Disease / surgery
  • Humans
  • Male

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • sutimlimab

Associated data

  • ClinicalTrials.gov/NCT03347396